Sionna Therapeutics, Inc. (SION)
NASDAQ • Healthcare
Last close at September 16, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 49 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Sionna Therapeutics’ bottom line came in slightly below expectations as EPS of -$0.66 trailed the -$0.65 estimate (difference -$0.01) in the second fiscal quarter of 2026, based on preliminary results reported August 6, 2026. The early-stage cystic fibrosis-focused biotech posted a GAAP net loss of about $29.9 million, down 65.4% from about $18.1 million a year ago, alongside GAAP operating income of roughly -$32.5 million as it continued funding its pipeline work. EPS of -$0.66 was down 61.0% from -$0.41 in the year-ago quarter. Cash use remained elevated, with negative operating cash flow of about $44.1 million during the period. For the next period, consensus calls for EPS of -$0.63.
About Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector that researches and develops medicines for cystic fibrosis. The company is an early-stage drug developer rather than a commercial business, with its work centered on advancing a pipeline of cystic fibrosis candidates from Phase 1 through Phase 2 and Phase 2a proof-of-concept studies.
Today's Snapshot
SION closed 2.3% higher on heavier trading than usual. Sionna Therapeutics raised $120 million in funding led by Forbion, a biotech investor.
Trading Volume
Above 10d avg 1.3M
1.9M
vs S&P 500 Today
Outperforming Market
+2.91%
Updated: September 16, 2026 at 20:09 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$7.39 - $31.93Sell
- RSI (14)31.28Neutral
- Stochastic %K (14, 3, 3)59.09Neutral
- MACD Level (12, 26)-4.15Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.